[1] CAPORARELLO N, LIGRESTI G. Vascular Contribution to Lung Repair and Fibrosis. Am J Respir Cell Mol Biol. 2023;69(2):135-146.
[2] KOUDSTAAL T, FUNKE-CHAMBOUR M, KREUTER M, et al. Pulmonary fibrosis: from pathogenesis to clinical decision-making. Trends Mol Med. 2023;29(12):1076-1087.
[3] WANG X, ZHOU J, LI X, et al. The Role of Macrophages in Lung Fibrosis and the Signaling Pathway. Cell Biochem Biophys. 2024;82(2):479-488.
[4] BEHR J, SALISBURY ML, WALSH SLF, et al. The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions. Am J Respir Crit Care Med. 2024;210(4):392-400.
[5] DOWMAN LM, HOLLAND AE. Pulmonary rehabilitation in idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2024;30(5):516-522.
[6] JIANG M, BU W, WANG X, et al. Pulmonary fibrosis: from mechanisms to therapies. J Transl Med. 2025;23(1):515.
[7] CHEN S, SONG X, LV C. Macrophages and Pulmonary Fibrosis. Curr Mol Med. 2025;25(4):416-430.
[8] WU KC, CHANG YH, DING DC, et al. Mesenchymal Stromal Cells for Aging Cartilage Regeneration: A Review. Int J Mol Sci. 2024;25(23):12911.
[9] SHAN Y, ZHANG M, TAO E, et al. Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges. Signal Transduct Target Ther. 2024;9(1):242.
[10] LI M, LI J, WANG Y, et al. Umbilical cord-derived mesenchymal stem cells preferentially modulate macrophages to alleviate pulmonary fibrosis. Stem Cell Res Ther. 2024;15(1):475.
[11] XIAO K, LIU C, WANG H, et al. Umbilical cord mesenchymal stem cells overexpressing CXCR7 facilitate treatment of ARDS-associated pulmonary fibrosis via inhibition of Notch/Jag1 mediated by the Wnt/β-catenin pathway. Biomed Pharmacother. 2023;165:115124.
[12] FARGE D, LOISEL S, LANSIAUX P, et al. Mesenchymal stromal cells for systemic sclerosis treatment. Autoimmun Rev. 2021;20(3):102755-102767.
[13] ZHOU C, ZHANG B, YANG Y, et al. Stem cell-derived exosomes: emerging therapeutic opportunities for wound healing. Stem Cell Res Ther. 2023;14(1):107-124.
[14] WANG J, ZHANG H, LI J, et al. Exosome-derived proteins in gastric cancer progression, drug resistance, and immune response. Cell Mol Biol Lett. 2024; 29(1):157.
[15] SONAR S, DAS A, KALELE K, et al. Exosome-based cancer vaccine: a cell-free approach. Mol Biol Rep. 2025;52(1):421.
[16] ZONOUZ AM, RAHBARDAR MG, ALIBOLANDI M. Exosome-based platforms for treatment of multiple sclerosis. Brain Res Bull. 2025;222:111256.
[17] MATSUZAKA Y, YASHIRO R. Therapeutic Strategy of Mesenchymal-Stem-Cell-Derived Extracellular Vesicles as Regenerative Medicine. Int J Mol Sci. 2022; 23(12):6480.
[18] LI H, BAI L. Advances in mesenchymal stem cell and exosome-based therapies for aging and age-related diseases. Stem Cell Res Ther. 2025;16(1):401.
[19] LI Y, SHEN Z, JIANG X, et al. Mouse mesenchymal stem cell-derived exosomal miR-466f-3p reverses EMT process through inhibiting AKT/GSK3β pathway via c-MET in radiation-induced lung injury. J Exp Clin Cancer Res. 2022;41(1):128.
[20] HAO X, LI P, WANG Y, et al. Mesenchymal Stem Cell-Exosomal miR-99a Attenuate Silica-Induced Lung Fibrosis by Inhibiting Pulmonary Fibroblast Transdifferentiation. Int J Mol Sci. 2024;25(23):12626.
[21] SUN Q, HU J, YU P, et al. Peptide PD29 treats bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β/smad signaling pathway. Exp Lung Res. 2019; 45(5-6):123-134.
[22] NEMOTO M, KOO CW, SCANLON PD, et al. Combined Pulmonary Fibrosis and Emphysema: A Narrative Review. Mayo Clin Proc. 2023;98(11):1685-1696.
[23] SAVIN IA, ZENKOVA MA, SEN’KOVA AV. Pulmonary Fibrosis as a Result of Acute Lung Inflammation: Molecular Mechanisms, Relevant In Vivo Models, Prognostic and Therapeutic Approaches. Int J Mol Sci. 2022;23(23):14959.
[24] DUAN R, HONG CG, WANG X, et al. Olfactory mucosa mesenchymal stem cells alleviate pulmonary fibrosis via the immunomodulation and reduction of inflammation. BMC Pulm Med. 2024;24(1):14.
[25] LEE H, JEONG OY, PARK HJ, et al. Promising Therapeutic Effects of Embryonic Stem Cells-Origin Mesenchymal Stem Cells in Experimental Pulmonary Fibrosis Models: Immunomodulatory and Anti-Apoptotic Mechanisms. Immune Netw. 2023;23(6):e45.
[26] CHATTOPADHYAY S, RAJENDRAN RL, CHATTERJEE G, et al. Mesenchymal stem cell-derived exosomes: A paradigm shift in clinical therapeutics. Exp Cell Res. 2025;450(1):114616.
[27] SUN ZL, YOU T, ZHANG BH, et al. Bone marrow mesenchymal stem cell-derived exosomes miR-202-5p inhibited pyroptosis to alleviate lung ischemic-reperfusion injury by targeting CMPK2. Kaohsiung J Med Sci. 2023;39(7):688-698.
[28] REN Q, XU Y, XU L, et al. Hypoxic bone marrow mesenchymal stem cell-derived exosomal lncRNA XIST attenuates lipopolysaccharide-induced acute lung injury via the miR-455-3p/Claudin-4 axis. Int Immunopharmacol. 2023;125(Pt A):111066.
[29] SHARMA A, WAIRKAR S. Flavonoids for treating pulmonary fibrosis: Present status and future prospects. Phytother Res. 2024;38(9):4406-4423.
[30] ZHU X, ZENG B, WU C, et al. Inhibition of TGF-β2-Induced Trabecular Meshwork Fibrosis by Pirfenidone. Transl Vis Sci Technol. 2023;12(11):21.
[31] ISHIDA Y, KUNINAKA Y, MUKAIDA N, et al. Immune Mechanisms of Pulmonary Fibrosis with Bleomycin. Int J Mol Sci. 2023;24(4):3149.
[32] CHEN W, PENG J, TANG X, et al. MSC-derived exosome ameliorates pulmonary fibrosis by modulating NOD 1/NLRP3-mediated epithelial-mesenchymal transition and inflammation. Heliyon. 2024;11(2):e41436.
[33] GIFFORD CC, TANG J, COSTELLO A, et al. Negative regulators of TGF-β1 signaling in renal fibrosis; pathological mechanisms and novel therapeutic opportunities. Clin Sci. 2021;35(2):275-303.
[34] JI Z, LIN S, GUI S, et al. Overexpressed Poldip2 Incurs Retinal Fibrosis via the TGF-β1/SMAD3 Signaling Pathway in Diabetic Retinopathy. Diabetes. 2024;73(10): 1742-1755.
[35] WANG J, XIA Z, QING B, et al. DsbA-L activates TGF-β1/SMAD3 signaling and M2 macrophage polarization by stimulating AKT1 and NLRP3 to promote pulmonary fibrosis. Mol Med. 2024;30(1):228.
[36] SONG J, SUN DL, LI CY, et al. TL1A Promotes Fibrogenesis in Colonic Fibroblasts via the TGF-β1/Smad3 Signaling Pathway. Curr Med Sci. 2024;44(3):519-528.
[37] ZHU D, ZHANG Q, LI Q, et al. Inhibition of AHNAK nucleoprotein 2 alleviates pulmonary fibrosis by downregulating the TGF-β1/Smad3 signaling pathway. J Gene Med. 2022;24(9):e3442.
[38] LEE JS, CHO HG, LEE JW, et al. Influence of Transforming Growth Factors beta 1 and beta 3 in the Scar Formation Process. J Craniofac Surg. 2023;34(3):904-909.
[39] YAO F, XU M, DONG L, et al. Sinomenine attenuates pulmonary fibrosis by downregulating TGF-β1/Smad3, PI3K/Akt and NF-κB signaling pathways. BMC Pulm Med. 2024;24(1):229-246.
[40] AN B, FANG Y, WANG L, et al. Inhibition of TGF-β1/Smad3 signaling by compound 5aa: A potential treatment for idiopathic pulmonary fibrosis. Bioorg Chem. 2024;14(7):107374-107382.
[41] LIANG Y, TANG X, ZHANG X, et al. Adipose Mesenchymal Stromal Cell-Derived Exosomes Carrying MiR-122-5p Antagonize the Inhibitory Effect of Dihydrotestosterone on Hair Follicles by Targeting the TGF-β1/SMAD3 Signaling Pathway. Int J Mol Sci. 2023;24(6):5703.
[42] DU J, WU J, SONG Q, et al. Mesenchymal stem cell exosomes regulate TGFβ/Smad3 by decreasing the METTL3-NEAT1 axis to inhibit scar progression after breast surgery. J Mol Histol. 2025;56(3):161. |